Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-w
An open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was safe and well tolerated and supports its further optimization as a treatment alternative.
